After outperforming the SOC again, the FDA should

After outperforming the SOC again, the FDA should assign the 2-dose regimen of LL as the new SOC and make the 4-dose treatment the trial dosage to compare vs. the SOC to prove/disprove the company claim that the 4-dose tx works significantly better than the 2-shot. Gotta love the news from the CSP patient. Way to go, LL - back these FDA crooks into a corner with results until they can't say no!